Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies

Diseases of the Esophagus

Volumn 29, Issue 8, 2016, Pages 1107-1114

  Lin, G ^a,b   Han, S Y ^a,b   Xu, Y P ^a,b,c   Mao, W M ^b,c  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c Zhejiang Key Lab of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophagus)   (China)

Author keywords

chemoradiotherapy; esophageal cancer; interval; neoadjuvant therapy; surgery

Indexed keywords

ADJUVANT CHEMORADIOTHERAPY; ANASTOMOSIS LEAKAGE; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HUMAN; LONG TERM SURVIVAL; META ANALYSIS; MORBIDITY; MORTALITY RATE; OVERALL SURVIVAL; PREOPERATIVE RADIOTHERAPY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; TIME FACTOR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; MALE; MIDDLE AGED; MORTALITY; NEOADJUVANT THERAPY; PROCEDURES; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STATISTICS AND NUMERICAL DATA;

AGED; CHEMORADIOTHERAPY, ADJUVANT; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84999740060     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/dote.12432     Document Type: Article

References (20)

1. Kamangar F, Dores G M, Anderson W F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137–2150.
2. van Hagen P, Hulshof M C, van Lanschot J J et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012; 366: 2074–2084.
3. Tepper J, Krasna M J, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086–1092.
4. Shaikh T, Ruth K, Scott W J et al. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg 2015; 99: 270–276.
5. Sjoquist K M, Burmeister B H, Smithers B M et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 2011; 12: 681–692.
6. Shapiro J, van Hagen P, Lingsma H F et al. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg 2014; 260: 807–813, discussion 13–4.
7. Kalady M F, de Campos-Lobato L F, Stocchi L et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 2009; 250: 582–589.
8. Tulchinsky H, Shmueli E, Figer A, Klausner J M, Rabau M. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008; 15: 2661–2667.
9. Chiu C H, Chao Y K, Chang H K et al. Interval between neoadjuvant chemoradiotherapy and surgery for esophageal squamous cell carcinoma: does delayed surgery impact outcome? Ann Surg Oncol 2013; 20: 4245–4251.
10. Martin L W. What is the optimal interval between chemoradiation and esophagectomy? Semin Thorac Cardiovasc Surg 2012; 24: 87–89.
11. Tessier W, Gronnier C, Messager M et al. Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer? Ann Thorac Surg 2014; 97: 1181–1189.
12. Kim J Y, Correa A M, Vaporciyan A A et al. Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg 2012; 93: 207–212, discussion 12–3.
13. Koshy M, Greenwald B D, Hausner P et al. Outcomes after trimodality therapy for esophageal cancer: the impact of histology on failure patterns. Am J Clin Oncol 2011; 34: 259–264.
14. Ruol A, Rizzetto C, Castoro C et al. Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: does delayed surgery have an impact on outcome? Ann Surg 2010; 252: 788–796.
15. Rizk N P, Venkatraman E, Bains M S et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007; 25: 507–512.
16. Kelsen D P, Winter K A, Gunderson L L et al. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 2007; 25: 3719–3725.
17. Gilbert S, Martel A B, Seely A J et al. Prognostic significance of a positive radial margin after esophageal cancer resection. J Thorac Cardiovasc Surg 2014; 149: 548–555.
18. Moore H G, Gittleman A E, Minsky B D et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004; 47: 279–286.
19. Bartels H, Stein H J, Siewert J R. Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg 1998; 85: 840–844.
20. Aminian A, Panahi N, Mirsharifi R et al. Predictors and outcome of cervical anastomotic leakage after esophageal cancer surgery. Jpn J Cancer Res Ther 2011; 7: 448–453.